| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 109, 960-965, Copyright © 1981 by Endocrine Society
ARTICLES |
LM Braley, A Menachery and GH Williams
To evaluate the role of angiotensin II (A II) in mediating the steroidogenic response to angiotensin I (A I) and tetradecapeptide, rat glomerulosa cells were incubated with each peptide in the presence or absence of an angiotensin-converting enzyme inhibitor (captopril or the nonapeptide bradykinin-potentiating factor). Both A I and tetradecapeptide increased aldosterone secretion in a dose-dependent fashion, but were considerably less effective (P less than 0.001) than the same dose (2.4 X 10(-9) M) of A II. In addition, both A I and tetradecapeptide caused a dose-dependent increase in A II accumulation in the incubation media, indicating that part of their steroidogenic effect is indirect via conversion to the octapeptide. While captopril (1.0 X 10(-4) M) almost completely blocked A I (2.4 X 10(-8) M)-induced A II accumulation, it caused only a 50% reduction (P less than 0.01) in aldosterone output. The nonapeptide-converting enzyme inhibitor (2.3 X 10(-6) M) produced a similar blockade. This lack of complete inhibition of A I-induced steroidogenesis suggests that A I also has a direct effect on the glomerulosa cells, i.e. 50% of the activity of A I is due to intrinsic activity. On the other hand, converting enzyme inhibitors did not affect tetradecapeptide-induced aldosterone output or A II accumulation, making it impossible to determine if it has a direct steroidogenic effect. The failure of converting enzyme inhibitors to modify tetradecapeptide-induced accumulation of A II suggests that an enzyme other than converting enzyme is responsible for its generation.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |